Get the Stockscreener App
1.88
3.59%
-0.07
Pre-market:
1.98
0.10
+5.32%
Imunon Inc stock is traded at $1.88, with a volume of 57,557.
It is down -3.59% in the last 24 hours and down -24.50% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
57,557
Relative Volume:
0.60
Market Cap:
$7.90M
Revenue:
$125.00K
Net Income/Loss:
$-14.64M
P/E Ratio:
-0.3638
EPS:
-5.1674
Net Cash Flow:
$-15.06M
1W Performance:
-6.93%
1M Performance:
-24.50%
6M Performance:
-51.55%
1Y Performance:
-87.36%
1-Day Range:
$1.86
$1.975
1-Week Range:
$1.86
$2.15
52-Week Range:
$1.86
$15.39
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.88 | 8.19M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imunon Inc Stock (IMNN) Latest News
IMNN Q1 2026 Earnings: Narrowing Loss Beats Estimates as Clinical Progress ContinuesOne-Time Loss Impact - newsline.com
Imunon (IMNN) chair receives stock grant and updates IRA holdings - Stock Titan
Imunon (IMNN) CEO Stacy Lindborg granted 1,593 shares as salary stock - Stock Titan
IMNN Q1 2026 Earnings: Narrower-Than-Expected Loss Per Share as Company Advances PipelineDividend Increase Stocks - newsline.com
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN) - MSN
Imunon Secures 10 Million Dollars Funding for Ovarian Cancer Trial - HarianBasis.co
Imunon Secures 10 Million Dollar Funding for Ovarian Cancer Trial - sekbernews.id
Imunon IMNN Q4 2025 Earnings Transcript - AOL.com
Imunon stock rises on $10M financing for cancer trial By Investing.com - Investing.com India
Imunon stock rises on $10M financing for cancer trial - Investing.com
IMUNON Secures Up to $10 Million Financing to Advance Phase 3 Ovarian Cancer Trial - citybiz
Imunon Secures $10 Million Non-Dilutive Structured Financing - TipRanks
Imunon Secures $10 Million Financing From Streeterville Capital; Issues Preferred Stock and Notes - TradingView
Imunon (Nasdaq: IMNN) secures $10M structured financing for Phase 3 OVATION 3 - Stock Titan
IMUNON Announces Up to $10 Million Cash Financing - GlobeNewswire
Imunon, Inc. announced that it has received $10 million in funding - marketscreener.com
IMNN Q1 2026 Earnings: Narrower Loss Per Share Surpasses Analyst ExpectationsEarnings Revision Upgrade - The Legal Advocate
Imunon Inc. (IMNN) Holds Steady Near Support as Traders Eye Breakout PotentialFactor ETF Flow - The Legal Advocate
Imunon Shares Trade Early After CEO Gets Stock Grant - Bez Kabli
IMNN Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesEPS Consistency Score - newsline.com
Imunon (IMNN) Executive Chairman awarded 3,484 shares in stock-based salary - Stock Titan
Imunon (IMNN) director granted 5,557 shares in lieu of board fees - Stock Titan
Imunon (IMNN) director receives 11,148-share stock grant in lieu of board fees - Stock Titan
Imunon (IMNN) director takes board fees in 5,011-share stock grant - Stock Titan
Imunon (IMNN) director granted 10,330 shares as board fee compensation - Stock Titan
Imunon (IMNN) CEO Stacy Lindborg receives 1,491-share stock grant in lieu of cash pay - Stock Titan
Imunon Inc. (IMNN) Holds Steady at $2.20 as Trading Activity Reflects ConsolidationEase of Movement - newsline.com
Imunon Inc. (IMNN) Nudges Higher Amid Tight Trading RangeCalendar Spread Trade - Newser
IMNN Q1 2026 Earnings: Narrower-than-expected loss drives small share gainUpward Estimate Revision - newsline.com
IMNN Stock Price, Quote & Chart | IMUNON INC (NASDAQ:IMNN) - ChartMill
Imunon (IMNN.US) is scheduled to release its earnings report before the market opens on March 31. - Moomoo
Imunon (IMNN) Up +0.71% — 3 Reasons the Rally Could Continue 2026-05-21Ichimoku TK Cross - Newser
Imunon Earnings Call Balances Breakthroughs and Cash Strain - TipRanks
Why Is Imunon, Inc. (CLSN) Stock Up Today? - Meyka
Imunon (IMNN) Flat at $2.25 — Consolidation Continues 2026-05-19Moving Average Crossovers - newsline.com
Why Is Imunon, Inc. (CLSN) Stock Down Today? - Meyka
Imunon (IMNN) Slides -3.61% as Selling Pressure Mounts 2026-05-18Skew Index - Newser
Earnings call transcript: Imunon Inc. misses Q1 2026 EPS forecast, stock dips - Investing.com
Imunon targets OVATION 3 last patient enrollment in Q1 2029 while outlining preferred-share financing options - MSN
Armistice Capital (IMNN) discloses 396,718 shares, 9.99% stake - Stock Titan
Q1 2026 Imunon Inc Earnings Call Transcript - GuruFocus
IMNN SEC FilingsImunon Inc 10-K, 10-Q, 8-K Forms - Stock Titan
IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27 - Yahoo Finance
UK Housing Market Gloom Persists, RICS Survey Signals Continued WeaknessSocial Trade Signals - newser.com
Imunon (IMNN) Declines -3.00% Amid Market Weakness 2026-05-13AI Signals - newser.com
Imunon | 10-Q: Q1 2026 Earnings Report - Moomoo
Imunon, Inc. (NASDAQ:IMNN) Q1 2026 Earnings Call Transcript - Insider Monkey
Imunon Q1 2026 Earnings Preview - MSN
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):